U
ATOS icon

UBS’s Atossa Therapeutics ATOS Stock Holding History

UBS’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1
Closed -$4.92K – 10341
2014
Q2 		$4K Buy
+1
New +$3.89K ﹤0.01% 9635
2014
Q1 		– Hold
0
– -$1K – 10408
2013
Q4 		– Sell
-1
Closed -$6.58K – 10166
2013
Q3 		$8K Hold
1
– – ﹤0.01% 8997
2013
Q2 		$8K Buy
+1
New +$16.9K ﹤0.01% 8819

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

UBS's ATOS Position: Q3 2014 in Review

UBS sold out of Atossa Therapeutics (ATOS) in Q3 2014, closing a stake of 1 share — an estimated $4.92K sold.

UBS first reported a position in ATOS in Q2 2013 and held it in 3 quarters. The position peaked at $8K in Q3 2013. 12 funds tracked by Wall St. Rank hold ATOS as of Q3 2014.

  • UBS reported no remaining Atossa Therapeutics position as of Q3 2014 after selling out during the quarter.
  • UBS sold 1 Atossa Therapeutics share in Q3 2014, an estimated $4.92K.
  • UBS first reported a position in Atossa Therapeutics in Q2 2013 and held it in 3 quarters.
  • UBS's Atossa Therapeutics position peaked at $8K in Q3 2013.
  • 12 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.